Allakos, Inc.

27 articles with Allakos, Inc.

• Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

  10/21/2020

  Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-blind, placebo-controlled Phase 2 study of lirentelimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis (ENIGMA) in the New England Journal of Medicine (NEJM). All AK002 dose a

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• Allakos Initiates Patient Recruitment for AK002 Registrational Studies

  6/3/2020

  -- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the second half of 2021 --

• Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020

  5/21/2020

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of two oral abstract presentations at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress being held virtually from June 6 to 8, 2020. The following virtual oral abstract presentations will be available starti

• Allakos Reports First Quarter 2020 Financial Results

  5/11/2020

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020. First Quarter 2020 Financial Results Research and development expenses were $18.3 million in the first quarter of 2020 as compared to $15.1 million in the same period in 2019, an increase of $3.2 mil

• Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting   

  5/11/2020

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of an oral presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. The virtual presentation will take place on May 16, 2020 at 6:00pm ET. The abstract is currently available on the ASCRS

• Allakos Announces Positive Interim Results from an Open-Label Extension Study of Antolimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis

  5/4/2020

  -- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment -- REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported results from a long-term open-label extension (OLE) study of antolimab for the tre

• Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting

  4/21/2020

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting. The presentations will take place during the DDW Annual Meeting being held virtually from May 2 to 5, 2020. Access to all accepted abstracts,

• Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies

  3/24/2020

  Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported the initiation of three clinical studies of antolimab: a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD), a Phase 2/3 study in eosinophilic esophagitis (EoE), and a Phase 1 study of subcutaneously administered antolimab in healthy volunteers.

• Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

  3/24/2020

  Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported results from a Phase 1 study evaluating the safety and efficacy of antolimab for the treatment of patients with mast cell gastrointestinal disease.

• Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

  2/25/2020

  Allakos Inc. reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update of its ongoing and planned development activities.

• Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting

  2/24/2020

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results in a number of diseases where mast cells and/or eosinophils have been shown to play a role in disease pathology.

• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK

  1/6/2020

  Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

• ALLK LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation of Allakos Inc.

  12/19/2019

  Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Allakos Inc. from allegations that Allakos might have issued misleading information to the investing public..

• Allakos Reports Third Quarter 2019 Financial Results

  11/12/2019

  Allakos Inc., a biotechnology company developing antolimab for the treatment of eosinophil and mast cell related diseases, reported financial results for the third quarter ended September 30, 2019.

• Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

  10/28/2019

  Allakos Inc., a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, announced upcoming presentations at the American College of Gastroenterology 2019 Annual Scientific Meeting.

• 

  Clinical Catch-up for August 5-9

  8/12/2019

  Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
• 

  Roche Gets in on Bay Area Allakos' $100M Funding Round

  12/13/2017

  The round was led by NEA and included Redmile Group, Partner Fund Management, Rock Springs Capital, LifeSci Venture Partners, Samsara BioCapital, and a large institutional investor.

• Bay Area's Allakos Taps Former ZS Pharma CEO As New Leader

  8/15/2017

• Allakos Expands License Agreement With The Johns Hopkins University School of Medicine

  11/29/2016